Figure 3. Interleukin 2c (IL-2c) Treatment, Infiltration of T-Cells, Motor Neurons, and Glial-Cell Immunoreactivity in Spinal Cords of SOD1G93A Mice.
A-C, Representative micrographs of the ventral horns of lumbar spinal cords stained for CD3+ cells in wild-type mice, vehicle-treated SOD1G93A mice, and IL-2c–treated SOD1G93A mice; arrowheads indicate T-cells and insets show magnified T-cells. D-F, Representative micrographs of the ventral horns of lumbar spinal cords stained for NeuN in all 3 groups of mice. G-I, Micrographs stained for CD3+ cells and NeuN in disease end stages in wild-type mice, vehicle-treated SOD1G93A mice, and IL-2c–treated SOD1G93A mice. J, Quantification of CD3+ cells localized to the ventral horns of spinal cord sections (IL-2c–treated mice: mean [SD], 12.2 [6.1] cells; vehicle-treated mice: 4.4 [3.7] cells; P = .03). K-M, Representative micrographs of the ventral horns of lumbar spinal cords stained for Nissl in wild-type mice, vehicle-treated SOD1G93A mice, and IL-2c–treated SOD1G93A mice. N-P, Representative micrographs of the ventral horns of lumbar spinal cords stained for glial fibrillary acidic protein (GFAP) in all 3 groups of mice. Q-S, Representative micrographs of the ventral horns of lumbar spinal cords stained for CD11b at disease end stage in all 3 groups of mice. T, Quantification of motor neuron soma size from Nissl-stained spinal cord sections of IL-2c–treated SOD1G93A mice (mean [SD], 279.8 [28.6] μm2) compared with vehicle-treated mice (mean [SD], 167.4 [21.9] μm2; P = .001). U, Quantification of GFAP from spinal cord sections of IL-2c–treated SOD1G93A mice (mean [SD], 137.3% [43.0%]) compared with vehicle-treated mice (248.7% [49.7%]; P = .002). V, Quantification of cluster of differentiation molecule 11b (CD11b) immunoreactivity from spinal cord sections of SOD1G93A mice receiving IL-2c therapy (mean [SD], 79.8% [55.0%]) compared with vehicle-treated mice (179.4% [61.1%]; P = .02).